Britain and America have announced a landmark commercial pact that will maintain zero levies on UK pharmaceutical products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to boost funding on medicines through the National Health Service (NHS). This move secures that tariffs on these vital products will stay at nothing for a period of the next three years.
This agreement is in response to earlier warnings to hike import taxes on branded drug products, with figures floated up to one hundred percent.
"This agreement with the Britain bolsters the global environment for innovative medicines and brings much-needed fairness to American-British drug exports," an announcement noted.
Trade Impact
Drugs are one of the UK's biggest exports to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Trade data show that in the year prior to the third quarter, the UK sold drugs worth £11.1bn to the US. This amount represented 17.4% of British export trade in that timeframe.
"This deal secures work, stimulates funding and facilitates the UK to emerge as a international leader for medical research," a minister remarked.
Detailed UK Commitments
The agreement involves several specific changes from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be limited at 15%. Last year, rebates topped 20%.
Broader Context
This agreement follows a long-running tension between the drug companies and the ministers over drug pricing and regulatory access.
The disagreement were exacerbated by assertions that American consumers were charged several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the past decade.
